PASI75 at 4-12weeks
12 articles reporting 14 RCTs comparing 9 treatment arms,including
vehicle, tofacitinib, tapinarof,
benvitimod, calcipotriol,
roflumilast, Cal/BD, betamethasone, tacalcitol, halobetasol.The NMA
showed that all treatments except tofacitinib performed significantly
better than vehicle(Fig.2 and Supplemental table 2).We found that Cal/BD
and tapinarof had higher rank probabilities (SUCRA 91.5and 84.1
respectively) in terms of PASI75,followed by roflumilast, betamethasone
and benvitimod.
Safety oftopical therapies at 4–12
weeks
13 RCTs comparing among 11 treatments(including vehicle),according to
the SUCRA, tofacitinib had lower AEs than
Cal/BD(SUCRA 85 and 43.8
respectively), the highest probability for AEs was found with
tapinarof(SUCRA 1.2),followed by benvitimod and HP/TAZ(Supplemental
Table 4).Compared with vehicle,the highest odds of AEs were
tapinarof(OR 3.50 95%CI2.71 to
4.52),benvitimod(OR 2.68 95%CI1.91 to 3.77) and HP/TAZ(OR 1.92
95%CI1.29 to 2.87), the lowest odds
of AEs were tofacitinib(OR 0.85 95%CI0.57 to 1.27) and
betamethasone(OR 0.89 95%CI0.62 to
1.29). (Table 1 and supplemental figure 3b ).
Tolerability of topical
therapies at 4–12 weeks
We measured tolerability of drugs
from withdrawal data due to adverse events.15 RCTs reported the
tolerability by comparing 10 treatments. The highest odds of withdrawal
were with tapinarof(OR 3.97
95%CI1.14 to 13.89) and benvitimod(OR 3.23 95%CI1.33 to 7.82) that
compared with vehicle. (Supplemental Table 3).According to the SUCRA,the
betamethasone and roflumilast had highest tolerability(SUCRA 86.3 and
83.3 respectively). (Supplemental Table 4)